Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 19/20 | 0.67 |
| ▸ | PPARG | P37231 | 18/20 | 0.67 |
| ▸ | PPARD | Q03181 | 11/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5113158 | 1.00 | PPARA (0.67) | PPARAPPARGPPARD | |
| SCHEMBL5114063 | 0.92 | PPARA (0.79) | PPARAPPARGPPARD | |
| SCHEMBL5114055 | 0.92 | PPARA (0.79) | PPARAPPARGPPARD | |
| SCHEMBL14265728 | 0.90 | PPARA (0.67) | PPARAPPARGPPARD | |
| SCHEMBL4034249 | 0.85 | PPARG (0.65) | PPARAPPARGPPARD | |
| SCHEMBL14265725 | 0.84 | PPARA (0.79) | PPARAPPARGPPARD | |
| SCHEMBL14265730 | 0.84 | PPARA (0.79) | PPARAPPARGPPARD | |
| SCHEMBL5115912 | 0.81 | PPARA (0.80) | PPARAPPARGPPARD | |
| SCHEMBL4030508 | 0.81 | PPARA (0.68) | PPARAPPARGPPARD | |
| SCHEMBL5123614 | 0.81 | PPARA (1.00) | PPARAPPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7345070-B2 | Side effects reduction; Diabetes mellitus, Syndrome X, Type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, atherosclerosis; 3-{4-[2-(2-phenyl-5-methyl-oxazol-4-yl)-ethoxy]-phenyl}-2-methyl-2-phenoxy-propionic acid | ELI LILLY AND COMPANY (US) | 2008-03-18 | — | — | US | disclosed |
| EP-1313716-B1 | OXAZOLYL-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | LILLY CO ELI (US) | 2007-05-02 | — | — | EP | disclosed |
| US-20050245584-A1 | Peroxisome proliferator activated receptor agonists | BROOKS DAWN A | 2005-11-03 | — | — | US | disclosed |
| US-6930120-B2 | Oxazolyl-arylproplonic acid derivatives and their use as ppar agonists | ELI LILLY AND COMPANY (US) | 2005-08-16 | — | — | US | disclosed |
| US-20040097590-A1 | Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists | BROOKS DAWN ALISA (US) | 2004-05-20 | — | — | US | disclosed |
| EP-1313716-A1 | OXAZOLYL-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | ELI LILLY AND COMPANY (US) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002016331-A1 | OXAZOLYL-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | ELI LILLY AND COMPANY (US) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097590-A1 | Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists | PPARA, PPARG, PPARD | PPARA 1/4885PPARG 2/4885PPARD 3/4885 |
| US-20050245584-A1 | Peroxisome proliferator activated receptor agonists | PPARG, PPARA, PPARD | PPARA 2/4885PPARG 1/4885PPARD 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.